Literature DB >> 25739857

Glycemic Variability Determined by Continuous Glucose Monitoring System Predicts Left Ventricular Remodeling in Patients With a First ST-Segment Elevation Myocardial Infarction.

Masaomi Gohbara1, Noriaki Iwahashi, Shunsuke Kataoka, Yoshikazu Hayakawa, Kentaro Sakamaki, Eiichi Akiyama, Nobuhiko Maejima, Kengo Tsukahara, Kiyoshi Hibi, Masami Kosuge, Toshiaki Ebina, Satoshi Umemura, Kazuo Kimura.   

Abstract

BACKGROUND: Impaired glucose metabolism plays an important role in patients with acute myocardial infarction, but the clinical significance of glycemic variability (GV) early after the onset of ST-segment elevation myocardial infarction (STEMI) remains to be fully elucidated. METHODS AND
RESULTS: We prospectively investigated the clinical impact of GV, as determined by a continuous glucose monitoring system (CGMS), on left ventricular remodeling (LVR) assessed by cardiac magnetic resonance imaging (CMR) in 69 patients (63±13 years, 59 men) with a first reperfused STEMI within 12 h of onset. All patients were equipped with a CGMS when in a stable phase after admission and underwent repeat CMR at baseline and 7 months follow-up. Patients were divided into 2 groups according to the mean amplitude of glycemic excursions (MAGE). Patients in the upper tertile of MAGE were categorized as group High (H) and the other two-thirds as group Low (L). LVR was defined as an absolute increase in left ventricular end-diastolic volume index of ≥20%. LVR more frequently occurred in group H than in group L (56% vs. 11%, P<0.001). Multivariate analysis showed the higher MAGE group was an independent predictor of LVR in the chronic phase (odds ratio, 13.999; 95% confidence interval, 3.059 to 64.056; P=0.001).
CONCLUSIONS: MAGE early after the onset of STEMI identified patients with LVR in the chronic phase.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25739857     DOI: 10.1253/circj.CJ-14-1226

Source DB:  PubMed          Journal:  Circ J        ISSN: 1346-9843            Impact factor:   2.993


  10 in total

Review 1.  Definition of left ventricular remodelling following ST-elevation myocardial infarction: a systematic review of cardiac magnetic resonance studies in the past decade.

Authors:  Damien Legallois; Amir Hodzic; Joachim Alexandre; Charles Dolladille; Eric Saloux; Alain Manrique; Vincent Roule; Fabien Labombarda; Paul Milliez; Farzin Beygui
Journal:  Heart Fail Rev       Date:  2022-01       Impact factor: 4.214

2.  Glycemic variability determined with a continuous glucose monitoring system can predict prognosis after acute coronary syndrome.

Authors:  Hironori Takahashi; Noriaki Iwahashi; Jin Kirigaya; Shunsuke Kataoka; Yugo Minamimoto; Masaomi Gohbara; Takeru Abe; Kozo Okada; Yasushi Matsuzawa; Masaaki Konishi; Nobuhiko Maejima; Kiyoshi Hibi; Masami Kosuge; Toshiaki Ebina; Kouichi Tamura; Kazuo Kimura
Journal:  Cardiovasc Diabetol       Date:  2018-08-18       Impact factor: 9.951

3.  Glycemic variability in type 2 diabetes mellitus and acute coronary syndrome: liraglutide compared with insulin glargine: a pilot study.

Authors:  Maria Isabel Del Olmo-García; David Hervás Marín; Jana Caudet Esteban; Antonio Ballesteros Martin-Portugués; Alba Cerveró Rubio; Miguel Angel Arnau Vives; Ana Catalá Gregori; Maite Penalba Martínez; Juan Francisco Merino-Torres
Journal:  J Int Med Res       Date:  2020-06       Impact factor: 1.671

4.  Insulin resistance and dysglycemia are associated with left ventricular remodeling after myocardial infarction in non-diabetic patients.

Authors:  Chen Die Yang; Ying Shen; Lin Lu; Feng Hua Ding; Zhen Kun Yang; Rui Yan Zhang; Wei Feng Shen; Wei Jin; Xiao Qun Wang
Journal:  Cardiovasc Diabetol       Date:  2019-08-07       Impact factor: 9.951

5.  Glycemic Control Status and Long-Term Clinical Outcomes in Diabetic Chronic Total Occlusion Patients: An Observational Study.

Authors:  Xuehui Zhang; Maoxiao Nie; Xue Chen; Zhe Liang; Quanming Zhao
Journal:  J Interv Cardiol       Date:  2021-04-21       Impact factor: 2.279

6.  Higher levels of TWEAK and matrix metalloproteinase-3 during the acute phase of myocardial infarction are associated with adverse left ventricular remodeling.

Authors:  Ferhat Eyyupkoca; Cengiz Sabanoglu; Mehmet Sait Altintas; Ajar Kocak; Karabekir Ercan; Nilnur Eyerci; Sercan Okutucu
Journal:  Postepy Kardiol Interwencyjnej       Date:  2021-12-28       Impact factor: 1.426

7.  Significance of day-to-day glucose variability in patients after acute coronary syndrome.

Authors:  Machiko Miyoshi; Hiroyasu Uzui; Tomohiro Shimizu; Takayoshi Aiki; Yuichiro Shiomi; Minoru Nodera; Hiroyuki Ikeda; Naoto Tama; Kanae Hasegawa; Tetsuji Morishita; Kentaro Ishida; Shinsuke Miyazaki; Hiroshi Tada
Journal:  BMC Cardiovasc Disord       Date:  2021-10-10       Impact factor: 2.298

8.  Visit-to-visit fasting plasma glucose variability is associated with left ventricular adverse remodeling in diabetic patients with STEMI.

Authors:  Chen Die Yang; Ying Shen; Feng Hua Ding; Zhen Kun Yang; Jian Hu; Wei Feng Shen; Rui Yan Zhang; Lin Lu; Xiao Qun Wang
Journal:  Cardiovasc Diabetol       Date:  2020-09-02       Impact factor: 9.951

9.  Glycaemic Variability and Hyperglycaemia as Prognostic Markers of Major Cardiovascular Events in Diabetic Patients Hospitalised in Cardiology Intensive Care Unit for Acute Heart Failure.

Authors:  Edouard Gerbaud; Ambroise Bouchard de La Poterie; Thomas Baudinet; Michel Montaudon; Marie-Christine Beauvieux; Anne-Iris Lemaître; Laura Cetran; Benjamin Seguy; François Picard; Fritz-Line Vélayoudom; Alexandre Ouattara; Rémi Kabore; Pierre Coste; Pierre Domingues-Dos-Santos; Bogdan Catargi
Journal:  J Clin Med       Date:  2022-03-11       Impact factor: 4.241

10.  Association between Changes in the Systolic Blood Pressure from Evening to the Next Morning and Night Glucose Variability in Heart Disease Patients.

Authors:  Tomohiro Shimizu; Hiroyasu Uzui; Yusuke Sato; Machiko Miyoshi; Yuichiro Shiomi; Kanae Hasegawa; Hiroyuki Ikeda; Naoto Tama; Yoshitomo Fukuoka; Tetsuji Morishita; Kentaro Ishida; Shinsuke Miyazaki; Hiroshi Tada
Journal:  Intern Med       Date:  2021-06-05       Impact factor: 1.271

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.